Literature DB >> 28383168

Different free prostate-specific antigen to total prostate-specific antigen ratios using three detecting systems.

Hui-Qing Huang1,2, Yan Zhang1, Hua-Guo Xu1.   

Abstract

BACKGROUND: Prostate-specific antigen (PSA) is used as an indicative marker of a pathologic condition of the prostate, and the ratio of free PSA (fPSA) to total PSA (tPSA) helps to distinguish benign prostatic hyperplasia (BPH) from prostate cancer (PCa). In this study, we present some reversed ratios of fPSA to tPSA and analyze the possible mechanism.
METHODS: Using the UniCel DxI800 Access Immunoassay System, eight reversed fPSA to tPSA ratios were obtained, and then these samples were retested with an Abbott Architect i2000 Immunoassay Analyser and Cobas e602.
RESULTS: Four of the eight reversed ratios kept a ratio >1 using Abbott Architect i2000, and seven of them turned into a ratio <1 using Cobas e602.
CONCLUSION: In consideration of the assay these three detecting systems apply, the possible reason of the reversed ratios can be heterophile antibodies. To get accurate reason, further study is required.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  immunoenzymatic assay; prostate-specific antigen; reversed ratio

Mesh:

Substances:

Year:  2017        PMID: 28383168      PMCID: PMC6817054          DOI: 10.1002/jcla.22231

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  5 in total

1.  Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin.

Authors:  H Lilja; A Christensson; U Dahlén; M T Matikainen; O Nilsson; K Pettersson; T Lövgren
Journal:  Clin Chem       Date:  1991-09       Impact factor: 8.327

2.  Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors.

Authors:  A Christensson; C B Laurell; H Lilja
Journal:  Eur J Biochem       Date:  1990-12-27

3.  Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.

Authors:  H I Scher; W K Kelly
Journal:  J Clin Oncol       Date:  1993-08       Impact factor: 44.544

Review 4.  Prostate-specific antigen: biochemistry, analytical methods, and clinical application.

Authors:  D A Armbruster
Journal:  Clin Chem       Date:  1993-02       Impact factor: 8.327

Review 5.  Prostate-specific antigen and human glandular kallikrein: two kallikreins of the human prostate.

Authors:  P Henttu; P Vihko
Journal:  Ann Med       Date:  1994-06       Impact factor: 4.709

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.